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Effect of Anti-Cyclic Citrullinated 
Peptide and HLA-DRB1 Subtypes 
on Clinical Disease Activity Index in 
Rheumatoid Arthritis Patients 
INTRODUCTION
RA is a chronic autoimmune disease and the most common 
inflammatory joint disease has a global prevalence of approximately 
0.5%-1% in adults. RA characterized by the presence of RF and anti-
citrullinated protein/peptide autoantibodies [1-3]. The incidence and 
prevalence of RA vary depending on the geographical region [4].
RA is a chronic disease with numerous degenerative effects on 
joints. Auto immune disease and genetic factors which are HLA-
DRB1 and its subtypes follow different patterns in different races 
and communities [1]. RA course varies widely, making the prognosis 
difficult in individual patients.
Although no factor has been determined as the main and primary 
beginner of the disease, there is some evidence indicating that 
synovial inflammation is likely to result from the complex interactions 
among environmental, genetic and immunologic factors, leading to 
deregulation in the immunity system and disruption of auto tolerance 
process. The finding that auto antibodies such as RF and anti-CCP 
could be found in patients’ serum long before clinical stage confirms 
the above theory [4,5].
The rate of contribution of genetic factors to RA is varied in 
different studies due to the interaction between the genes and 
environment. System of Human Leukocyte Antigen (HLA) plays a 
role in development of rheumatic diseases in different individuals 
with different characteristics. The risk of acquiring RA is mainly 
associated with allelic variation in HLA-DRB1 gene which encodes 
the beta chain of MHC-II molecules [4]. 
Preliminary studies indicated that 70% of RA patients had HLADR4, 
much higher than 28% of the control group. This association 
was more pronounced in the patients with anti-CCP production. 
Pathogenic alleles of HLA-DRB1 have a shared amino acid 
sequence at position 70-74 in the third hypervariable region of the 
HLA-DR beta chain, called Shared Epitope (SE) [6].
In 2010, American College of Rheumatology classification criteria 
(1987) for RA was revised [7]. Recently revised criteria (in 2010) 
specifies the scores 0-10 and the score ≥ 6 confirms diagnosis 
of RA. The criteria are as follows: the number of involved joints, 
serology tests (titres of RA and anti-CCP), markers of acute phase 
response and duration of symptoms [7].
Van Beers JJ et al., study in the Netherlands reported that anti-
citrullinated fibronectin antibodies were positively correlated with 
HLA type and SE alleles in RA patients [8]. Ucar F et al., found 
HLA*01, HLA*04, and HLA*09 as the most frequent alleles and 
HLA*013 as the least frequent allele associated with RA in east 
Black Sea Turkish population [9]. 
Mackie SL et al., conducted a study in England to investigate 
different HLA in anti-CCP-positive patients with RA and found that 
subgroups of HLA-DRB1*0401 and HLA-DRB1*0404 contributed 
to the pathogenesis of RA [10]. Naqi N et al., concluded that HLA-
DRB1 (*04) was highly frequent in patients with RA, but in the control 
group, HLA-DRB1 (*11) was found as the most frequent allele with 
potentially protective role against RA [11]. 
S Zodaray P et al., found that anti-CCP was highly important for RA 
diagnosis and an important factor in RA progression and radiologic 
changes. Also, anti-CCP production was highly associated with 
genetic, underlying factors like HLADRB1 [12].
In Chaharmahal va Bakhtiari province (Southwestern Iran), with 
regard to consanguineous marriages and specific ethnicities, no 
study on rheumatologic diseases, including RA and genetic and 
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ABSTRACT
Introduction: Rheumatoid arthritis (RA) is a crippling disease 
with a global prevalence of approximately 0.5%-1% in adults. 
Genetic, environmental and immunologic factors contribute 
importantly to pathogenesis of RA. American College of 
Rheumatology (ACR) assists in early diagnosis of the disease. 
Aim: The aim of this study was to investigate the effects of HLA-
DRB1 gene and anti-Cyclic Citrullinated Peptide (CCP) antibody 
on Clinical Disease Activity Index (CDAI) and to determine the 
frequency of HLA-DRB1 alleles in the patients with RA. 
Materials and Methods: In this descriptive-analytical study, 64 
patients with RA referring rheumatology clinic of Hajar Hospital, 
Shahr-e-Kord, Iran were enrolled based on ACR criteria (1987) 
by convenience sampling. All patients were examined to assess 
primary CDAI and referred to laboratory for serologic tests 
[Rheumatoid Factor (RF) and anti-CCP]. After the patients’ DNA 
was extracted, HLA-DRB1 was determined per single specific 
primer-polymerase chain reaction by inno-train kits. The patients 
were re-examined six months later.
Results: The most prevalent type of HLA-DRB1 in the studied 
patients was 04. In patients with HLA-DRB1 (04), HLA-DRB1 
(01), and HLA-DRB1 (15), CDAI decreased pronouncedly after 
six months, but in other patients it did not (p<0.05). Of the 
patients, 81.3% had high titers of anti-CCP, but no association 
between anti-CCP and CDAI was found.
Conclusion: RA could be a multifactorial disease. The patients 
with HLA-DRB1 (04), HLA-DRB1 (01) and HLA-DRB1 (15) showed 
a good response to routine treatments. The patients with HLA-
DRB1 (04) are likely to have no decrease in secondary CDAI. 
High titers of anti-CCP in patients may indicate the severity of 
RA in the studied region and perhaps environmental, genetic 
and unknown or idiopathic factors are aetiologically crucial. 
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RESULTS
1. Effect of HLA-DRB1 Gene Subtypes on CDAI
The most frequent HLA in the studied patients was HLA-DRB1 (04) 
followed by HLA-DRB1 (11) and HLA-DRB1 (01) [Table/Fig-1].
In 64 patients under study the highest initial CDAI was obtained 24 
with range 7.81±5.13. CDAI in the patients with the most prevalent 
HLA-DRB1 subtypes decreased in number after 6 months, with a 
significant difference (p<0.05). Initial CDAI and the CDAI six months 
later in HLA-DRB1 (01) was p=0.043 and paired t-test showed this 
decrease was significant.
Initial CDAI in HLA-DRB1 (11) increased six months later, but this 
increase was not significant. The CDAI six months later decreased 
compared to initial index in all patients, but this decrease was not 
significant [Table/Fig-2].
2. Effect of Anti-CCP Antibody on CDAI
For anti-CCP, 15.6% of the patients were negative (titre of < 30), 
3.1% had low titre (less than or equal tripled the maximum normal 
titre), and 81.3% had high titre (more than tripled the maximum 
normal titre) [4].
Out of 54 patients with common HLA subtypes, the most frequent 
(83.3%) patients had high anti-CCP titre followed by 14.8% of the 
patients with negative titre and 1.9% with low titre. 
CDAI decreased pronouncedly in patients with positive, high titre 
anti-CCP, but no significant difference between anti-CCP titre and 
CDAI was seen in all patients [Table/Fig-3].
No statistically significant difference between anti-CCP and the 
initial CDAI and the CDAI six months later (p=0.0164, p=0.0372, 
respectively).
3. Demographic Characteristics
Out of the studied patients, 10.9% were male and 89.1% were 
female. In addition, 70.3% of the patients had no family history of 
RA. A total of 26% of the patients were RF-negative, and the rest 
was of (+1) to (+4). The mean age of samples was 49.5±13.09 year 
and the duration of suffering from disease was 9.7±7.9 year.
serological associations, has been yet conducted and no data on 
RA gene mapping and prevalence, especially with RF or anti-CCP 
positivity, are available. Therefore, this study was conducted for the 
first time in this province to determine the relative frequency of HLA-
DRB1 alleles and to investigate the effect of these alleles and anti-
CCP antibody on CDAI in RA patients to pave the way for more 
comprehensive research. 
MATERIALS AND METHODS
In this retrospective, case control and prospective study, the study 
population consisted of all patients with definite diagnosis of RA 
according to American College of Rheumatology criteria. The study 
was performed in rheumatology clinic of Hajar Hospital affiliated to 
Shahr-e-Kord University of Medical Sciences, Iran. Sample size was 
64 patients referring the clinic from May 2010 to August 2012 with RA 
definite diagnosis made by rheumatologist were enrolled. Data were 
recorded in the checklists after giving the initial explanations to the 
patients, a complete physical examination, and obtaining history of the 
disease carefully. Necessary information including demographic data 
(such as age and gender), disease period, taken drugs, preliminary 
examination results, serologic markers (RF, anti-CCP, ESR, and CRP), 
and CDAI was recorded in a questionnaire. Patients with concurrent 
septic arthritis were excluded from the study. Data were recorded in 
checklists to make a detailed comparison between the indicators in 
question after six months. Almost 5 ml blood sample was taken from 
the patients enrolled for serologic tests (RF, anti-CCP, ESR, and CRP). 
Then, blood samples containing EDTA, as anticoagulant, were trans-
formed to a cellular and molecular research center for molecular 
tests and HLA-typing, and DNA was extracted by phenol-chloroform 
method. 
Spectrophotometry was run to check the quality and quantity of the 
extracted DNA. After extraction of DNA in the laboratory by phenol 
chloroform method, various subtypes of HLA-DRB1 were detected 
per single specific primer-PCR using inno-train kits (Germany). 
In this study, a modified PCR, namely Sequence Specific Priming 
(SSP) PCR was used, in which only 3’ end of the primer is responsible 
for building the specific allele under investigation. For complete 
analysis of SSP, numerous amplifications were run simultaneously. 
Only the samples that contain the sequences complementary to the 
primers in each well produced the PCR product, and indeed each 
sample produced product in only one or few wells (depending on the 
type of serotype). Therefore, each sample’s serotype was specified. In 
addition, there was a pair of common primers (internal primer) inside 
all the wells, which was complementary to the sequence existing in 
all serotypes and hence a band was developed in all 24 wells (except 
negative control). PCR products were analyzed by agarose gel. 
The results were interpreted based on the tables provided by the kit 
manufacturer. These tables provided us with the data regarding the 
length of each well product (the expected size of DNA bands and 
internal control band in each well). 
For anti-CCP, the patients were divided into three groups, positive 
low titre, positive high titre, and negative. Then, the patients’ HLA 
was determined. HLA-DR alleles were classified based on anti-CCP 
classification, and the CDAI was accordingly determined and recorded. 
Patients received a usual medical intervention and were re-examined 
six months later with no dropout in 64 patients. A new questionnaire 
was filled out for them and the CDAI was determined. At the end of 
the intervention the variations in the CDAI, as an indicator of response 
to the treatment, in different groups were compared. The CDAI was 
determined based on the number of sensitive joints, the number 
of swollen joints, patient’s assessment, and clinical examination of 
patients [5]. By measuring CADI and determining anti-CCP antibody 
in patients, the association between them was examined. 
STATISTICAL ANALySIS
The data were analyzed by SPSS software using descriptive 
statistics, correlation tests, and Chi-square.
hlA-drb1 subtypes frequency %
04 20 3.31
11 15 4.23
01 10 6.15
15 9 1.14
10 4 3.6
14 3 7.4
07 2 1.3
16 1 6.1
Total 64 100
[Table/Fig-1]: A comparison of frequency among the most prevalent HLA-DRB1-
subtypes in the studied patients.
[Table/Fig-2]: Comparison of severity of the initial CDAI* and the CDAI six months 
later in HLA-DRB1 subtypes in RA patients. 
* Clinical disease activity index
 hlA type CdAI Mean±Sd p-value
HLA-DRB1(04)
Initial 9.32±5.78
0.002
Six months next 5.22±3.23
HLA-DRB1(11)
Initial 5.93±3.78
0.197
Six months next 8.83±6.76
HLA-DRB1(15)
Initial 8.4±3.93
0.045
Six months next 4.6±3.18
Prevalent HLAs
Initial 7.75±4.95
0.046
Six months next 5.94±4.73
Total
Initial 5.13±7.81
0.66
Six months next 4.86±6.25
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No statistically significant difference between the type of HLA and 
gender, and between RA severity and gender was observed (p>0.05). 
No significant difference was observed between gender and age of 
the patients (M=52.4±16 and F= 49.1±12 year), between gender 
and disease duration (M= 8.2±9, F= 9.3±7 year), and between 
gender and CDAI (M=8.1±5, F=7.7±5), (p>0.05).
In patient with common HLA subtypes, based on one-way Kruskal–
Wallis test, the age (p=0.349), anti-CCP antibody (p=0.085), and 
CDAI (p=0.123) did not show statistically significant difference and 
only disease duration in HLA 15 was significantly higher than other 
HLAs (p<0.05). Moreover, the chi-square test showed no statistically 
significant difference between gender and type of HLA (p=0.145) 
and between family history and the type of HLA (p=0.213). No 
significant association was found between HLA type and severity 
of RF, and between anti-CCP and HLA type in RA patients, as well 
(p=0.927 and 0.498, respectively).
DISCUSSION
Because of the insidious and progressive nature of RA, in the 
absence of timely diagnosis and appropriate treatment, it can lead 
to complications and disability in patients, and leaving the cycle of 
economic activity by the patients and their crippling lead to high 
costs for individual and community. This study was carried out to 
pave the way for further investigations regarding this disease and 
other rheumatologic diseases and to do appropriate planning with 
regard to the prevalence of seropositivity in the early detection of the 
disease so that RA-related complications and disability rate could 
be reduced as much as possible.
In this study, the frequency of HLA-DRB1 types was reported: type 
04 (0.31.3%), type 11(23.4%), type 01(15.6%), and type 15 (15.6%). 
Therefore, the most frequent allele was type HLA-DRB1 04, called 
SE, in the studied patients, which is consistent with many similar 
studies, such as Ucar F et al., study in Turkey, Naqi N et al., study 
in Pakistan, Mitsunagu et al., study in Japan, Ben Hamed M et al., 
study in Tunisia, and Farouk HM et al., study in Egypt [9,11,13-
15]. This allele can increase the predisposition to RA and may be 
associated with RA prognosis [16]. 
In different studies, the prevalence of some subtypes was obtained 
higher in different races and regions worldwide. For example, in 
a Turkish population of the patients with RA, the prevalence of 
HLA subtypes 09, 04, and 01, and in a Tunisian population, the 
prevalence of HLA-DRB1 04 was higher. Even, in different provinces 
of Iran varied prevalence has been obtained for different subtypes. 
For example, a study in Zahedan-Iran, Sistan va Baluchestan 
showed that the prevalence of HLA-DRB1 0110 was higher [17]. 
In another study on RA patients in Khorasan-Iran, the prevalence of 
HLA subtype DQ5 was higher [18].
Since a direct correlation between HLA system particularly HLA-DR4 
subgroups, more specifically HLA-DR1, and RA, RF, and/or positive 
anti-CCP has been reported in several studies, determination of 
HLA and above factors may predict the outcome of the disease and 
assist in developing the type of therapy. This argument could be 
explained by the potential resistance, from the RA onset, to primary 
medications used for its treatment with increased titre of anti-CCP 
and RF, and presence of certain HLAs.
It seems that multifactorial behaviors contribute to RA development. 
We found that the patients with HLA-DRB1 15, 01, and 04 showed 
suitable responses to the routine therapies. It is not consistent 
with what has been mentioned in the scientific resources and 
the patients with HLA-DRB1 04 are likely to have no decrease in 
secondary CDAI. High titres of anti-CCP antibody in the patients 
may be representative of the severity of RA disease in the province 
under study, and other genetic and environmental factors could be 
aetiologically important. More comprehensive studies could further 
elucidate this issue. 
In examining the relationship of CDAI with HLA type and anti-CCP, 
we found that this index significantly decreased compared to the 
second examination only in the groups of the patients with HLA-
DRB1 01, 04, and 15, and no significant difference was seen in 
other groups of the patients. This finding could be due to different 
responses of patients with different HLAs to pharmacologic therapies 
including Disease-Modifying Antirheumatic Drugs (DMARDs). 
In the patients with HLA-DRB1 11 consisting of 15 individuals, CDA1 
increased after six months unexpectedly, but this increase was not 
significant. Due to small number of patients, this finding cannot be 
definitely commented on, and definite explanation requires more 
comprehensive research. This HLA type may be associated with 
more severity of the disease.
In the present study, no significant relationship between HLA and 
anti-CCP, RF, and initial CDAI was found. This finding confirms Lu 
Z et al., study in China finding that HLA-DR4 was not associated 
with DAS28, anti-CCP and RF, but PAD4 was associated with 
disease activity (DAS28) and anti-CCP. On the other hand, STAT4 
is associated with DAS28 and RF. A potential laboratory error in 
measuring anti-CCP titre could be another reason for this finding 
[19]. 
No relationship between CDAI and anti-CCP confirms the results 
of Laki J et al., in Sweden and Montes A et al., in Spain. In Montes 
A et al., study, lack of association was due to high specificity and 
negative anti-citrullinated alpha-enolase in the patients with anti-
CCP [20,21].
In the present study, the initial decrease in CDAI and the decrease 
in CDAI six months later were not significant in all patients. It seems 
that a larger sample size will help to achieve more acceptable results. 
Notably, this decrease was significant for most patients. 
The effective genetic factors (HLA-DRB1 and sub-types) follow 
different patterns in different communities and races. The obtained 
specific patterns can be further completed in future studies [1].
The CDAI decreased after six months only in the patients with 
HLA-DRB1 04, 01, and 15 subtypes, and no statistically significant 
difference was observed in other groups of the patients.   
According to the results of statistical analysis of the data, and 
statistically significant differences in the association between HLA 
type and CDAI, it can be concluded that patients with HLA-DRB1 
04, 01, and 15 responded to the RA routine therapies suitably. 
The study of anti-CCP antibody frequency in patients with common 
HLAs revealed that 54 patients had the most frequent alleles. Most 
(83.3%) patients had anti body titres higher than 3, which is consistent 
with some studies [16]. Perhaps, these results indicate the severe 
and progressive nature of the disease in the province under study. 
More accurate conclusions require more comprehensive studies in 
this region and other regions of the country. 
Consistent with other studies, the present study found that anti-CCP 
antibody could have an effective role in diagnosis and determination of 
disease prognosis. Almost 84% of the patients were positive for anti-
CCP antibody. In the patients who were negative for anti-CCP antibody, 
the role of RF or other immunity factors could be stronger [1].
Anti-CCP antibody f CdAI Mean±Sd p-value
Negative
10 Initial 5.8±4.76
0.817
Six months next 5.45±2.92
Low
2 Initial 3.5±0.0707
0.817
Six months next 3.5±1.41
High
52 Initial 8.3±5.17
0.066
Six months next 6.51±5.21
Total
64 Initial 7.8±5.13
0.66
Six months next 6.25±4.8
[Table/Fig-3]:  Comparison of severity of the initial CDAI* and the CDAI six months 
later in HLA-DRB1 subtypes in RA patients for different titers of anti-CCP  
* Clinical disease activity index
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In this study, only the association between HLA-DRB1 15 and 
duration of disease was statistically significant in the HLAs obtained 
from patients. Further similar studies need to be done in this field, 
because no similar finding was seen in the literature to the best of 
our knowledge [20].
In this study, the frequency of RF with regard to its effective role 
in developing and diagnosing the disease (with sensitivity and 
specificity of about 90%) was considered and found similar to other 
studies’ findings because 74% of the studied patients were positive 
for RF (1+ to 4+), which confirms the crucial role of RF in early 
diagnosis of RA [1].
According to the role of specific HLAs and genetic patterns of the 
patients in RA disease, family history of the disease was expected 
to be high. Almost 30% of the studied patients had family history 
of RA, but 70.3% of the patients did not. Therefore, the role of 
environmental and genetic factors could be pronounced and hence 
complementary studies in this area are needed to compare the effect 
of environmental (such as smoking, mineral oil, and silicon), infectious 
(such as Epstein-Barr virus, parvovirus B19, Streptococcus, and 
Mycoplasma), and other genetic factors to derive more acceptable 
results [4].
The mean age of the patients in the present study was 49.4 years, 
which was similar to the mean age of the patients with RA in different 
communities [4].
The patients with HLA-DRB1 04 in the present study exhibited a 
better response to the therapies compared to other patients. But 
in the Mori S et al., study in Japan, HLA-DRB1 04 was associated 
with more severity of the disease and drug resistance to DMARDs 
[22]. This inconsistency in the findings could be explained by the 
difference in genetic factors other than HLA.
LIMITATION
Limitations of this study include the cost of expensive tests to 
determine HLA and two stages of the study required to follow up the 
patients. Another problem was related to communicating with the 
patients to have them refer for subsequent examination and follow 
up and the patients migrating to other regions. Finally, 64 patients 
were present both at onset and till the completion of the study.
With further study to evaluate the type and dose of drugs leading 
to remission or low disease activity in patients with different HLA 
subtypes and different anti CCP titres, valuable findings on the 
RA severity and its association with the patients’ genetic features 
could be obtained. Study of the association between immunologic 
factors, such as PTPN22, STAT4, and PAD4, and RA clinical course 
is recommended in future investigations.
CONCLUSION 
RA could be a multifactorial disease. The patients with HLA-DRB1 
(04), HLA-DRB1 (01) and HLA-DRB1 (15) showed a good response 
to routine treatments. The patients with HLA-DRB1 (04) are likely 
to have no decrease in secondary CDAI. High titers of anti-CCP in 
patients may indicate the severity of RA in the studied region and 
perhaps environmental, genetic and unknown or idiopathic factors 
are aetiologically crucial.
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